| Literature DB >> 19451712 |
A E Paniz-Mondolfi1, A M Pérez-Alvarez, G Lanza, E Márquez, J L Concepción.
Abstract
In the Americas, approximately 20 million people suffer from the chronic phases of Chagas' disease, of which chagasic cardiomyopathy is the most important clinical feature. The elimination of Trypanosoma cruzi is a pivotal step in arresting the evolution of the disease. Unfortunately, currently available chemotherapy is mostly ineffective due to its limited efficacy and toxic side effects. The following case highlights the efficacy of new diagnostic and follow-up methods in the evaluation of novel trypanocidal compounds such as amiodarone and itraconazole. Copyright 2009 S. Karger AG, Basel.Entities:
Mesh：
Substances：
Year: 2009 PMID： 19451712 DOI： 10.1159/000219436
Source DB: PubMed Journal: Chemotherapy ISSN： 0009-3157 Impact factor: 2.544